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Features, mutational hot spots, and ezogabine treatment of
11 patients
ABSTRACT
Objective: To advance the understanding of KCNQ2 encephalopathy genotype–phenotype rela-
tionships and to begin to assess the potential of selective KCNQ channel openers as targeted
treatments.
Methods: We retrospectively studied 23 patients with KCNQ2 encephalopathy, including 11
treated with ezogabine (EZO). We analyzed the genotype–phenotype relationships in these and
70 previously described patients.
Results: The mean seizure onset age was 1.8 6 1.6 (SD) days. Of the 20 EEGs obtained within
a week of birth, 11 showed burst suppression. When new seizure types appeared in infancy (15
patients), the most common were epileptic spasms (n5 8). At last follow-up, seizures persisted in
9 patients. Development was delayed in all, severely in 14. The KCNQ2 variants identified intro-
duced amino acid missense changes or, in one instance, a single residue deletion. They were
clustered in 4 protein subdomains predicted to poison tetrameric channel functions. EZO use
(assessed by the treating physicians and parents) was associated with improvement in seizures
and/or development in 3 of the 4 treated before 6 months of age, and 2 of the 7 treated later; no
serious side effects were observed.
Conclusions: KCNQ2 variants cause neonatal-onset epileptic encephalopathy of widely varying
severity. Pathogenic variants in epileptic encephalopathy are clustered in “hot spots” known to be
critical for channel activity. For variants causing KCNQ2 channel loss of function, EZO appeared
well tolerated and potentially beneficial against refractory seizures when started early. Larger,
prospective studies are needed to enable better definition of prognostic categories and more
robust testing of novel interventions.
Classification of evidence: This study provides Class IV evidence that EZO is effective for refrac-
tory seizures in patients with epilepsy due to KCNQ2 encephalopathy. Neurol Genet 2016;2:e96;
doi: 10.1212/NXG.0000000000000096
GLOSSARY
BFNE 5 benign familial neonatal epilepsy; EZO 5 ezogabine.
In addition to underlying the majority of autosomal dominant cases of benign familial neonatal
epilepsy (BFNE), heterozygous variants in KCNQ2 occurring de novo or inherited from
a mosaic parent can lead to severe developmental impairment. This was first suggested in the
reports of small families with seizures persisting beyond infancy and intellectual disability.1–4 In
2012, a pivotal collaborative study screened 80 patients with early-onset epileptic encephalop-
athy and found novel KCNQ2 variants in 8.5 Since then, additional examples of “KCNQ2
encephalopathy” have been uncovered in other cohorts.6–12 The distribution of the first few
KCNQ2 encephalopathy variants in the structure of the encoded voltage-gated potassium
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channels implied their potential dominant-
negative effects on channel gating, conduc-
tion, or surface targeting.13 Indeed, initial
studies of those variants in vitro revealed such
strong loss of function (60%–90% reduced
current).14,15 A majority of known BFNE var-
iants are frameshifts and deletions predicted to
reduce the function by half; BFNE missense
variants usually exhibit only mild (5%–30%)
loss of function in vitro.16 These results sug-
gest that the varying severity of KCNQ2-
related epilepsy phenotypes may reflect the
differences between alleles in the degree of
KCNQ2 channel functional deficiency they
cause. Recent results indicate that Na1 chan-
nel blockers may have some degree of efficacy
against KCNQ2 encephalopathy by reducing
neuronal hyperactivity arising from KCNQ2
channel deficiency.12 Ezogabine (EZO) (Potiga;
GlaxoSmithKline, Philadelphia, PA) acts directly
on KCNQ2 channels, increasing their opening;
therefore, its use in cases where KCNQ2
variants diminish activity could be beneficial.
However, previously reported pediatric use of
EZO is limited to a single patient. Here, we
describe 23 additional cases of KCNQ2
encephalopathy, including 11 treated with EZO.
METHODS Patients. This is a retrospective study of patients
followed by pediatric neurologists and geneticists for KCNQ2
encephalopathy. All patients with neonatal-onset epilepsy,
developmental delay, and a pathogenic KCNQ2 variant detected
during routine clinical care between January 2012 andMarch 2014 by
J.J.M., K.L.P., T.T., B.B.-Z., L.C., R.F., P.M.L., E.M., S.N., V.N.,
X.R.O.-G., M.C.P., P.L.P., B.P., K.R., E.L.M., M.T., and C.V.
were included. Data (demographics; birth, seizure, family, and
developmental history; EEG, neuroimaging, and genetic test
results; and treatments, drug levels, and treatment responses)
were reported by their treating pediatric neurologists (22 patients)
and/or a consulting clinical geneticist (1 patient) via an anonymous
web-based RedCap survey.17 Seizure classification and magnetic
resonance neuroimaging findings were based on the assessment by
the treating pediatric neurologist (who directly reviewed the studies)
or the geneticist (who reviewed the reports).
EZO treatment. Ezogabine was prescribed as off-label use of an
approved drug, by individual treating neurologists based on their
risk-benefit assessment, as part of routine care. Parents were
counseled regarding known and potential unknown risks. EZO
was given 3 times daily, at milligrams-per-kilogram doses
extrapolated from recommendations in adults (table 1). Patients
were monitored for known side effects of chromaturia (red-brown
urine) and urinary retention18,19 at baseline and during periodic
urology visits, by renal/bladder ultrasound and parental diaper
counting, as determined by each clinician. No patients were begun
on treatment after the U.S. Food and Drug Administration
published a warning and revised labeling indicating that EZO can
cause retinal pigmentation abnormalities with potential risk of visual
loss.20–22 Parents of all patients under treatment at that time were
informed of the warning and its detailed content, and the risks and
benefits of continued treatment reassessed. Where treatment
continued after this warning, the recommended visual monitoring
was followed and included dilated funduscopic examinations and
assessment of visual fields. Commercial laboratories were used to
measure serum levels. Adult mean and 5%–95% range EZO
levels were estimated from a published pharmacokinetic model.23
Standard protocol approvals, registrations, and patient
consents. The retrospective anonymous physician survey was re-
viewed and exempted by the Colorado Children’s Hospital Insti-
tutional Review Board. The Rational Intervention for KCNQ2/3
Epileptic Encephalopathy (RIKEE) database and website (www.
RIKEE.org) was approved by the Baylor College of Medicine
Institutional Review Board.
Research questions and classification of evidence. This
study sought to provide additional information addressing the
question, “What are the clinical features of KCNQ2 encephalop-
athy, including genotype–phenotype relationships and pharma-
coresponsiveness?” The study provides Class IV evidence that
EZO is effective for the treatment of refractory seizures in patients
with epilepsy due to pathogenic KCNQ2 variants.
RESULTS Patient, family, and epilepsy characteristics.
Of the 23 patients, 12 were female (table e-1 at
Neurology.org/ng). Births occurred at a mean
gestational age of 38.6 6 1.16 weeks (SD). A family
history of seizures was reported for 5/23 patients.
Seizure onset was within the first 3 days of life for 22
patients and on the eighth day of life for 1. Initial
seizure frequency was multiple daily for 19 patients.
The initial seizure types, as reported by the treating
pediatric neurologist, were focal (n 5 9), tonic (n 5
6), myoclonic (n 5 4), mixed focal and generalized
(n5 1), generalized tonic-clonic (n5 1), and epileptic
spasms (n 5 1). Patients developed other seizure types
during infancy; the most common were epileptic spasms
(n 5 8). Seizures were refractory to 3 or more
anticonvulsants used alone or in combination in 21 of
the 23 patients. Nonetheless, seizures had remitted in 6
of the 12 who were under 2 years of age and in 8 of the
11 who were older than 2 years at last follow-up.
Spectrum of developmental impairment. Reporting
pediatric neurologists made assessments of the develop-
ment based on milestone achievement at follow-up.
For this cohort, mild impairment consisted of
appropriate milestones achieved slightly delayed for age,
moderate impairment consisted of achievement of most
milestones but temporally delayed by .50% (e.g.,
most walking supported, some speech and/or other
communication), and severe impairment consisted of
limited or no achievement of developmental milestones
in motor, language, and cognitive domains. No patients
had normal development. At last follow-up, development
was mildly abnormal in 3/23 patients, moderately
abnormal in 6/23, and severely abnormal in 14/23.
Some mildly to moderately impaired patients were
noted to exhibit autistic features. Other neurologic
2 Neurology: Genetics
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
impairments included hypotonia, dysphagia requiring
gastrostomy tube, dystonia, spastic quadriplegia,
abnormal eye movements, and cortical blindness.
Neonatal EEG and its evolution. A locally interpreted
EEG report from the first week of life was available for
20/23 patients; 11 showed burst suppression, 11 showed
dysmaturity and/or focal findings, and 1 was normal.
One ormore subsequent neonatal or post-neonatal EEGs
were available for 21 patients. One EEG continued to
show burst suppression with longer bursts and shorter in-
terburst intervals at 3 weeks old. Of the 20 other follow-
up EEGs, abnormalities included diffuse/multifocal
epileptiform discharges (n 5 11), diffuse background
slowing (n 5 6), background disorganization (n 5 6),
asymmetric background (n 5 2), and hypsarrhythmia
(n 5 20). The single normal follow-up EEG (at
3 months old) was of patient 1, a child mildly affected
in other respects: the neonatal EEG did not show burst
suppression, seizures remitted by 1 month old, and
developmental impairment was mild.
Neuroimaging. MRI scans were performed for 22 pa-
tients at a mean age of 4 months (range, 1 day to 22
months old); 16 were reported as normal. All abnormal
MRI scans except one (at 5 months old) were performed
within the first week of life. Abnormalities, as reported
by the treating pediatric neurologist, included diffuse
atrophy (n 5 3), periventricular increased white matter
signal (n 5 2), thin corpus callosum (n 5 3), and
increased diffusion in the bilateral globus pallidi (n5 1).
KCNQ2 variant classification. Sequencing revealed 17
different KCNQ2 variants. We assessed each test
result based on a set of criteria: (1) Was the newly
sequenced variant a recurring variant identified in
another KCNQ2 encephalopathy or BFNE patient
or pedigree? (2) Was it a substitution variant resulting
in a single amino acid change (i.e., a missense variant)?
(3) Was it inherited or de novo? (4) Was the variant
located in 1 of the 4 hot spots for the encephalopathy
phenotype, namely the S4 voltage-sensor, the pore, the
proximal intracellular calmodulin-binding helix, or the
distal calmodulin-binding helix?13 Answers to those
questions and the clinical features were considered in
developing a practical assessment of whether each
variant was likely to be pathogenic.
Of the 17 KCNQ2 variants found in our patients,
3 had been reported previously in single epileptic
encephalopathy patients, and 4 had been reported









mg/kg/d Side effects Clinical response
3 p.Asn190Ser 15 mo 2; 15 None reported No change
5 p.Arg201Cys 2 mo 10; 25 Somnolence No change
6 p.Arg201Cys 4 y 2.8; 12.8 None reported Parents report more discrete times of wakefulness and sleep, more
alertness, more smiling, some improvement in EEG with less
discontinuity in sleep, some sleep architecture, and less frequent
epileptiform dischargesa
9 p.Gly256Trp 15 mo 1; 19 Urinary retention
(resolved)
No change
11 p.Ala265Thr 2 y 2; 8 Urinary retention Improvement in development: alertness and interactionsa
12 p.Trp269Leu 4 mo 3.1; 20 None reported Improvement in seizures and development: seizures improved from
50–60/d to ,1/wk; can go up to 2 wk without any seizures. Also,
started to cry, started to hold head up, reach for objects, and play
with toysa
14 p.Thr274Met 2 y 4.5; 17.7 Urinary retention
(discontinued)
No change (discontinued)
15 p.Thr274Met 5 mo 9.5; 14 None reported Improvement in seizures: on modest doses, seizure-free except
with fevers; tried to lower dose and had breakthroughs; when dose
increased had resolution of seizures and improved responsivenessa
16 p.Thr274Met 3 y 0.7; 40 Urinary retention at
40 mg/kg/d, chromaturia
(resolved w/lower dose)
Improvement in seizures and development: epileptic spasms in
clusters; 2–3/d before and 0–1/d after, subsequent relapse to
1 cluster/day; parent report of increased alertness and tonea
18 p.Ala294Val 6 y 2.3; 12 None reported No change; no developmental improvement noted (seizures in
remission)
22 p.Ala337Thr 5 mo 8.5; 23 Urinary retention (only
at 23 mg/kg/d)
Improvement in seizures and development: seizures began to
decrease by the second week on 13 mg/kg/d; clearest EEG
response: before EZO, hypsarrhythmia with occasional periods with
organization for a few seconds; at 6 mo on EZO 23 mg/kg/d, EEG
had good organization, occasional slowing or spike wavea
Abbreviation: EZO 5 ezogabine.
a Indicates a positive response recorded by a parent or physician.
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in multiple unrelated epileptic encephalopathy pa-
tients. Surprisingly, 2 variants (identified in sib pairs
1, 2 and 19, 20) had been identified previously in
individuals with BFNE. The 8 remaining variants
were novel. One of the novel variants (identified in
patient 7) was shown to be inherited from a parent
with a BFNE history; 5 of the novel variants occurred
de novo; for 2 additional cases, parents had not been
tested. Lack of parental testing was typically due to
lack of insurance coverage.
Patients 1 and 2, a sibling pair, both exhibiting mild
developmental delay, harbored a missense variant,
p.Ser122Leu, a position that is outside the KCNQ2
encephalopathy hot zones. The father of patients 1
and 2 had recurrent seizures between 3 months and 2
years of age that remitted but recurred in adolescence; he
is now seizure-free without medication and of normal
intellect. Parental genetic testing was nevertheless not
performed. Notably, p.Ser122Leu was previously re-
ported in a pedigree with 3 affected individuals in 2
generations and normal developmental outcome in
all.24 Patient 7, who was mildly delayed developmentally
and had an abnormal EEG at 9 months of age, inherited
a previously unreported variant (p.Gln204His) from her
mother. The mother had been treated for neonatal seiz-
ures that remitted and remained seizure-free except for
a single seizure at 15 years of age. These 2 families pro-
vide examples of variable expressivity at the milder end
of the KCNQ2-related epilepsy spectrum.
Of the 17 KCNQ2 variants found, 16 resulted in
single amino acid substitutions (missense). The excep-
tion, a de novo single amino acid deletion (Phe305del),
was identified in identical twins (patients 19, 20). Our
review of the literature showed no previous examples of
single amino acid (or larger) deletions in KCNQ2
encephalopathy patients. Furthermore, Phe305del
was previously reported in a de novo case of BFNE,25
while patients 19 and 20 were profoundly delayed.
Review of the earlier case report suggested the possibil-
ity of mosaicism in the BFNE patient. The 17
KCNQ2 variants were mapped onto a model of the
channel’s functional domains (figure 1). In 8 cases, the
variant was within the voltage-sensor domain (5 within
the S4 helix). In 12 cases, the variant was within the
pore domain. The 3 remaining cases were within the
long C-terminal intracellular domain, within or near
the 2 calmodulin-binding helices.
Treatment with EZO. Eleven patients were treated on
a TID schedule with EZO, beginning at ages between
2 months and 6 years (table 1). Serum levels were
obtained prior to the first or second daily dose in 5
patients (9 measurements). We compared the pediatric
levels to a previously reported pharmacokinetic model
predicting adult peak (approximately 1 hour after oral
dosing) and trough (8 hours after dosing) mean levels
and ranges, based on a total of 15,420 adult serum
levels obtained during regulatory approval trials.23
Although the number of pediatric measurements was
insufficient to allow for detailed analysis, the pediatric
levels were all within the range seen in adults (figure 2).
Dose-related side effects observed included urinary
retention, chromaturia, and somnolence, which all
have been reported in adults.18,19 All resolved with
dose modification. Serious adverse side effects,
including ophthalmologic and skin pigmentary
changes included in the FDA black box warning,
were not reported during the follow-up period (mean,
11.5 months; range, 2–24 months). These adverse
effects were typically observed after 4 or more years of
treatment,20,21 which exceeded the amount of follow-up
available in our treated patients. Three of the 4 patients
treated at less than 6 months of age were reported to
exhibit improvement in seizures and development.
These patients had failed multiple standard
medication trials (at least 4) including several agents
with activity on voltage-gated sodium channels (1
tried phenytoin and all 3 responders tried topiramate
previously). Detailed dosing information regarding
these prior treatment trials was not obtained in our
survey. In patient 22, serial neonatal and before and
after EZO treatment EEGs were obtained (figure e-1).
The neonatal burst-suppression pattern evolved in early
infancy to hypsarrhythmia that proved refractory to
multiple medications (levetiracetam, topiramate,
clobazam, clonazepam, felbamate, phenobarbital,
valproic acid, and pyridoxine). Addition of EZO
was associated with the emergence of more
organization, but persistent intermittent slowing and
occasional epileptiform activity were also noted.
Notably, the 3 patients (patients 12, 15, and 22)
treated before 6 months of age and who showed
improvement had variants in or near the ion-
conducting pore domain. By contrast, the patient
treated before 6 months of age and who had no
response to EZO bore a variant in the S4 helix
(patient 5). In 7 patients who started EZO at a later
age, where seizures had remitted or were infrequent,
our survey tool provided less clear evidence of drug
effects. Patient 16, who started treatment when
3 years of age, had an improvement in seizures and
development according to the pediatric neurologist
and parents. One patient treated at 4 years of age
was reported to have improved alertness and EEG
background activity (patient 6); 1 patient whose
seizures had already remitted when treated at 2 years
of age had improvement in development only
(patient 11). The association between age groups
(,6 months and .6 months) and improved or
not improved seizure control with EZO treatment
is considered to be statistically significant (Fisher
exact test; 2-tailed p value 5 0.0242).
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DISCUSSION KCNQ2 variants arising de novo or,
more rarely, inherited from a parent have emerged as
an important cause of early-onset epileptic
encephalopathy. Including the present study, 93
KCNQ2 encephalopathy patients have been
reported so far.5–11,14,15,26,27 Considering all cases
reported with sufficient phenotypic detail (and
omitting a single gain-of-function outlier,
discussed below), the most consistent clinical
features are very early onset at 2.65 6 2.26 (SD)
days (n 5 88) with focal tonic seizures (89% n 5
84) and the transient appearance of burst
suppression in the EEG (62% n 5 86) within the
early neonatal period. In most patients, seizures are
Figure 2 EZO levels in infants and young children compared to adults at similar doses
Adult mean (middle line in bar) and 95%–5% range (top and bottom of bar) EZO levels are shown, along with the levels
measured in this study. Adult values at 1 and 8 hours after dosing are taken from a pharmacokinetic model fit to serum EZO
levels collected during regulatory trials.23 Adult doses of 300 mg TID (A) and 400 mg TID (B) correspond to 11.8 and 15.8
mg/kg/d, respectively (mean adult study patient weight was 76 6 16.5 kg, n 5 1,219). EZO levels measured in infants and
young children, indicated by circles (red, age 6–16 months; blue, age 19 months to 6 years) were within the range observed
for comparable doses in adults, and means were similar or somewhat higher than those measured in adults.
Figure 1 Type and distribution within KCNQ2 protein of variants in self-limiting epilepsy vs epileptic encephalopathy
Cartoon of KCNQ2 transmembrane topology, including intracellular amino (N) and carboxy (C) terminals, 6 transmembrane segments (S1–S6), and a pore
loop between S5 and S6 which partly enters the membrane. The calmodulin-binding segments within the intracellular C-terminal domain are indicated. (A)
Mutations found in BFNE/BFNIS/BFIS cases are distributed among all areas of the polypeptide sequence. Each symbol (n5 98) represents a de novo case or
a pedigree, placed at the location within the channel polypeptide corresponding to the sequenced genetic variant. Orange symbols (n 5 41) are missense
variants. Yellow symbols are all other variant types (i.e., loss of start codon, insertions or deletions changing frame, and premature stop codon). Encircled
regions, with the exception of the S4 helix, do not appear enriched in missense variants. (B) In patients with KCNQ2 encephalopathy, mutations are nearly
always single nucleotide substitutions resulting in a single amino acid change. In one instance (cases 19 and 20 of this series, 2 identical twins), a single
amino acid is deleted within an a-helix. Each red sphere represents an unrelated case. Encircled are the 4 hot spots for variants leading to epileptic
encephalopathy: the S4 voltage-sensor, the pore, the proximal C-terminal domain that binds phosphatidylinositol 4,5-bisphosphate (PIP2) and calmodulin
(CaM A), and the more distal domain which binds calmodulin (CaM B). Variant details for (A) are listed in table e-2; variant details for (B) are listed in table e-3.
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initially refractory and sometimes evolve through
infantile spasms and associated hypsarrhythmia to
eventual seizure freedom (73% n 5 83). Severe
intellectual disability (79% n 5 77) emerges in
early childhood. In later infancy and childhood,
autistic features (language and social impairment,
repetitive behaviors, outbursts including
potentially self-injurious behavior) are also notable.
Analysis of the first cases suggested a dominant-
negative effect as the basis for the severe phenotype in
these patients in contrast to the better outcomes in
BFNE.13 The clues supporting this hypothesis were that
the severe KCNQ2 variants were all missense (unlike
BFNE variants, which are diverse and include large
deletions) and that they were clustered in putative func-
tional hot spots, unlike BFNE variants, which are ran-
domly distributed throughout the channel polypeptide
(figure 1). Moreover, earlier, comprehensive studies of
transgenic mice overexpressing a dominant-negative
KCNQ2 variant had revealed a severe phenotype.13,28
Because KCNQ2 proteins form tetrameric channels
(either homotetramers consisting of KCNQ2 subunits
only or heterotetramers consisting of both KCNQ2 and
KCNQ3 subunits), variants of one subunit at certain
critical locations can poison the entire channel. Of the
variants identified in 93 KCNQ2 encephalopathy pa-
tients reported with clinical information, 86% are clus-
tered in 4 high-risk zones: the S4 voltage-sensor, the
pore, near the C-terminal proximal segment which
binds phosphatidylinositol 4,5-bisphosphate and cal-
modulin, and near the C-terminal B helix, which also
binds calmodulin.29 These observed high-risk zones
represent less than 20% of the KCNQ2 amino acids.
In the context of known potassium channel mecha-
nisms deduced from functional analysis and X-ray
crystallography, and initial in vitro studies,14,15 this
accumulated clinico-genetic evidence strongly supports
dominant-negative suppression as a primary factor
underlying severe phenotypes in a large majority of
KCNQ2 epileptic encephalopathy cases.13
The exceptions to the usual pattern merit careful
analysis. For example, patients 19 and 20, identical
twins, were severely affected and bore a single amino
acid deletion variant (Phe305del), the first deletion
to be reported in KCNQ2 encephalopathy. Notably,
a previous report described de novo deletion of the
same amino acid in a young female with a classical
BFNE phenotype.25 The published DNA sequencing
trace data from this earlier case, however, revealed
a relatively low abundance of the mutated allele com-
pared to the wild-type allele, raising the possibility of
unrecognized mosaicism. Indeed, 2 studies have iden-
tified families where a parent was mosaic for a KCNQ2
variant and had experienced BFNE, but their child,
a full heterozygote, exhibited severe epileptic enceph-
alopathy.5,30 Thus, sporadic, benign neonatal epilepsy
may be caused by a de novo germ line KCNQ2 variant
with a mild effect or by post-zygotic mosaicism for
a more severe variant. These findings illustrate that
screening for mosaicism and accurate variant classifi-
cation in individuals with apparent de novo KCNQ2
variants are crucial and have important implications
for reproductive counseling of such patients.
Three patients (1, 2, and 7), all mildly delayed,
had a parent with a history of neonatal seizures. A pre-
vious study noted mild developmental delay in 5 of
31 patients in a large KCNQ2 pedigree where other
family members exhibited classical BFNE and normal
development.31 Such variable expressivity may reflect
genetic or nongenetic factors and should be analyzed
through broader genetic testing in suitable families.
Previously reported experience with EZO treat-
ment of infants and children with KCNQ2-related
epilepsy is limited to 1 patient bearing the pore
variant p.Gly281Arg, who experienced a marked
reduction in seizure severity and frequency when
given 40 mg/kg before 22 months of age.11 Although
limited by a retrospective survey design and mod-
estly detailed treatment data, the current study de-
scribes 11 additional patients treated at ages ranging
from 2 months to 6 years. Overall, the patients tol-
erated these exposures well, with side effects that
were dose related, relatively minor, and reversible.
The clearest benefit was against refractory seizures,
when started before 6 months of age. Including the
previously reported case, 4 of 4 patients with pore
domain variants treated with EZO as infants experi-
enced what parents and treating doctors described as
a clearly positive influence on seizures. Experiments
in vitro using Xenopus oocytes have shown that one
of these pore domain variants, p.Thr274Met, strongly
reduces channel currents and that those effects were
reversed by EZO.15 In contrast, for patient 5, EZO at
2 months of age had no apparent effect on seizures. The
amino acid variant identified in this patient, p.
Arg201Cys, lies within the extracellular portion of the
S4 voltage sensor and has been shown to cause gain-of-
function by destabilizing the channel closed state.32 The
available results suggest that individuals with loss of
function may benefit, but those with gain-of-function
KCNQ2 variants may not benefit from treatment with
KCNQ2 openers. Notably, patient 6, also with p.
Arg201Cys, was treated between ages 4 and 6 years,
with apparent improvements in behavior and EEG.
Studies of larger numbers of patients will be needed
to assess such differences.
A recent study analyzed responses of 15 patients
with KCNQ2 encephalopathy to several approved
antiepileptic drugs, including the sodium-channel in-
hibitors carbamazepine, phenytoin, and oxcarbaze-
pine.12 Retrospective information was obtained
regarding medication dosage and seizure responses to
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each treatment. In this cohort, 11 patients experienced
remission or near remission to either carbamazepine or
phenytoin. Three patients had recurrence of seizures
following withdrawal of the anticonvulsant with return
of control after reintroduction, suggesting that at least
several of the responders required ongoing manage-
ment with the anticonvulsant in question. As in the
current study, due to the natural history of this disor-
der, with frequent resolution of seizures (but persis-
tence of developmental impairment) in infancy, the
lack of a second trial in the remaining responders
makes the assessment of response more difficult. Also,
as in the current series, the heterogeneity in cognitive,
language, and motor outcomes associated with differ-
ent KCNQ2 variants makes it difficult to determine
whether early seizure control treatment has affected
neurodevelopmental outcome. Further, until clearer
KCNQ2 encephalopathy clinical diagnostic criteria
emerge or an established pathogenic variant is detected,
concerns that carbamazepine can provoke infantile
spasms in susceptible patients is another reason for
caution.33
The current retrospective study highlights chal-
lenges in designing future targeted trials in KCNQ2
encephalopathy. Here, EZO was given after genetic
diagnosis, at minimum, months after birth and seizure
onset. EZO, though the first KCNQ2 channel opener
to obtain regulatory approval, has relatively modest
potency and selectivity.34–39 Newer agents, with
improved channel subtype-selectivity and greater
potency, have been identified, but remain at earlier
stages of development.38,39 Optimal testing of KCNQ2
openers as “precision medicines” for KCNQ2 loss-of-
function variants will require early diagnosis, clinical
advancement of more potent and selective agents, and
prospective trials.
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